Skip to main content
Premium Trial:

Request an Annual Quote

Specialty Labs to Begin Selling Roche s AmpliChip CYP450 Test by End of Month

NEW YORK, Oct. 10 (GenomeWeb News) - Clinical reference lab Specialty Laboratories said today that it has signed an agreement to begin co-marketing Roche Diagnostics' AmpliChip CYP450 assay by the end of the month.


The AmpliChip CYP450, which is built upon the Affymetrix microarray platform, analyzes the cytochrome P450 2D6 and 2C19 genotypes to help determine the appropriate dosages of medications for a variety of conditions, including pain medication, cardiac disease, cancer, and depression.


David Weavil, CEO of Specialty Laboratories, said in a statement that the assay "can help determine whether a standard dose of a drug metabolized in a patient with a particular genotype would be appropriate, or whether it might cause significant or serious side effects, or even toxicity." The test can also "predict whether a standard dosing schedule of expensive medications would be cleared from a person's body so quickly that it does not achieve effective therapeutic levels," Weavil said.


Specialty said that it also plans to launch a marketing campaign "to educate clients about the test's value."

The Scan

Boosters Chasing Variants

The New York Times reports that an FDA advisory panel is to weigh updated booster vaccines for COVID-19.

Not Yet

The World Health Organization says monkeypox is not yet a global emergency, the Washington Post reports.

More Proposed for Federal Research

Science reports that US House of Representatives panels are seeking to increase federal research funding.

PLOS Papers on Breast Cancer Metastasis, Left-Sided Cardiac Defects, SARS-CoV-2 Monitoring

In PLOS this week: link between breast cancer metastasis and CLIC4, sequencing analysis of left-sided cardiac defects, and more.